Modern progestogens in the treatment of genital endometriosis

Literature review

Authors

DOI:

https://doi.org/10.18370/2309-4117.2024.72.17-21

Keywords:

endometriosis, progestins, dienogest, Vigest-KV

Abstract

Objective of the review: to evaluate modern approaches to the use of progestogens for the treatment of endometriosis, using literature sources, to provide examples of their effectiveness in global and own practices.
Analysis of literary data. In total, 41 publications by foreign authors were selected and processed. Information on the effectiveness of the domestic progestogen drug Vigest-KV in the treatment of endometriosis in our own practice is also presented.
Today, the newest progestin is dienogest, a derivative of 19-nortestosterone. It has shown its high efficiency in various clinical manifestations of endometriosis, as well as in its recurrences. Long-term treatment regimens with dienogest (60 months) are promising, as they effectively reduce pain and the risk of endometriosis recurrence, in particular after surgical treatment. An important advantage of dienogest is the low frequency of side effects (1.2–2.5%), especially such as the effect on bone mineral density.
Our clinical experience allows us to recommend the Ukrainian medicinal product Vigest-KV, containing dienogest, for the treatment of various types of endometriosis. Its advantage is a special mechanism of ovulation blockade aimed at apoptosis of the granulosa cells of the growing follicle. Also, long-term use of this drug leads to the inhibition of follicle-stimulating and luteinizing hormones and a moderate decrease in the estradiol, the level of which is within the physiological parameters. This is very important to avoid the symptoms of estrogen deficiency while maintaining the anti-proliferative effect.
Conclusions. Today, the main method of treating endometriosis is hormone therapy. It not only reduces the clinical symptoms of endometriosis, but is also used before and after surgical treatment to reduce the risk of disease recurrence. Progestins (dienogest) are the most common hormonal method of treating endometriosis. Dienogest, as the most effective progestin, has a  pronounced anti-proliferative effect directed at the endometrium, as well as anti-inflammatory and immunomodulatory effects with a minimal risk of side effects. Dienogest in a dose of 2 mg/day provides a reduction in clinical symptoms, an improvement in the quality of life and preservation of reproductive function. Taking into account our own clinical experience of using Vigest-KV in various types of endometriosis, we can recommend its implementation into clinical practice.

Author Biographies

L.B. Markin, Danylo Halytsky Lviv National Medical University, Lviv

MD, professor, corresponding member of the NAMS of Ukraine, head of the Obstetrics and Gynecology Department

O.O. Matvienko, Danylo Halytsky Lviv National Medical University, Lviv

PhD, associate professor, Obstetrics and Gynecology Department

References

  1. Chapron C, Marcellin L, Borghese B, Santulli P. Rethinking mechanisms, diagnosis and management of endometriosis. Nat Rev Endocrinol. 2019. Nov;15(11):666-682. DOI: 10.1038/s41574-019-0245-z.
  2. Buck Louis GM, Hediger ML, Peterson CM, et al. Incidence of endometriosis by study population and diagnostic method: The ENDO study. Fertil Steril. 2011. Aug;96(2):360-5 DOI: 10.1016/j.fertnstert.2011.05.087
  3. Chamié LP, Ribeiro DMFR, Tiferes DA,et al. Atypical sites of deeply infltrative endometriosis: Clinical characteristics and imaging fndings. Radiographics. 2018. Jan-Feb;38(1):309-328. DOI: 10.1148/rg.2018170093
  4. Burney RO, Giudice LC. Pathogenesis and pathophysiology of endometriosis. Fertil Steril 2012;98:511–9. DOI: 10.1016/j.fertnstert.2012.06.029
  5. Giudice LC. Clinical practice. Endometriosis. N Engl J Med 2010;362: 2389–98. DOI: 10.1056/NEJMcp1000274
  6. Barra F, Grandi G, Tantari M, et al. A comprehensive review of hormonal and biological therapies for endometriosis: latest developments. Expert Opin Biol Ther. 2019. Apr;19(4):343-60. DOI: 10.1080/14712598.2019.1581761.
  7. Reis FM, Coutinho LM, Vannuccini S, et al. Progesterone receptor ligands for the treatment of endometriosis: The mechanisms behind therapeutic success and failure. Hum Reprod Update. 2020. Jun 18;26(4):565-585. DOI: 10.1093/humupd/dmaa009
  8. Barra F, Scala C, Ferrero S. Current understanding on pharmacokinetics, clinical efcacy and safety of progestins for treating pain associated to endometriosis. Expert Opin Drug Metab Toxicol. 2018;14(4):399–415. DOI: 10.1080/17425255.2018.1461840
  9. Lee JH, Song JY, Yi KW, et al. Efectiveness of Dienogest for Treatment of Recurrent Endometriosis: Multicenter Data. Reprod Sci. 2018;25(10):1515–22. DOI:10.1177/ 1933719118779733.
  10. Techatraisak K, Hestiantoro A, Ruey S, et al. Efectiveness of dienogest in improving quality of life in Asian women with endometriosis (ENVISIOeN): interim results from a prospective cohort study under real-life clinical practice. BMC Womens Health. 2019;19(1):68. DOI10.1186/s12905-019-0758-6.
  11. Vignali M, Belloni GM, Pietropaolo G, et al. Efect of Dienogest therapy on the size of the endometrioma. Gynecol Endocrinol. 2020. 2020 Aug;36(8):723-727. DOI:10.1080/09513590.2020.1725965.
  12. Angioni S, Pontis A, Malune ME, et al. Is dienogest the best medical treatment for ovarian endometriomas? Results of a multicentric case control study. Gynecol Endocrinol. 2020. Jan;36(1):84-86. DOI:10.1080/09513590.2019.1640674.
  13. Maggiore ULR, Ferrero S, Candiani M. Bladder Endometriosis: A Systematic Review of Pathogenesis, Diagnosis, Treatment, Impact on Fertility, and Risk of Malignant Transformation. Eur Urol. 2017;71(5):790–807. DOI:10.1016/j.eururo.2016.12.015.
  14. Angioni S, Nappi L, Pontis A, et al. Dienogest. A possible conservative approach in bladder endometriosis. Results of a pilot study. Gynecol Endocrinol Of J Int Soc Gynecol Endocrinol. 2015;31(5):406–8. DOI:10.3109/09513590.2015. 1006617.
  15. Leonardo-Pinto JP, Benetti-Pinto CL, Cursino K, Yela DA. Dienogest and deep infltrating endometriosis: The remission of symptoms is not related to endometriosis nodule remission. Eur J Obstet Gynecol Reprod Biol. 2017. Apr:211:108-111. DOI:10.1016/j. ejogrb.2017.02.015.
  16. Caruso S, Iraci M, Cianci S, et al. Efects of long-term treatment with Dienogest on the quality of life and sexual function of women afected by endometriosis-associated pelvic pain. J Pain Res. 2019;12:2371–8. DOI:10.2147/ JPR.S207599.
  17. Papíková Z, Hudeček R, Ventruba P, Szypulová M. Efcacy of dienogest treatment of clinical symptoms of rectovaginal endometriosis. Ces Gynekol. 2019;84(5):331–6.
  18. Kappou D, Matalliotakis M, Matalliotakis I. Medical treatments for endometriosis. Minerva Ginecol 2010;62:415–32.
  19. Yu Q, Zhang S, Li H, et al. Dienogest for treatment of endometriosis in women: A 28-week, open-label, extension study. J Women’s Heal. 2019. Feb;28(2). DOI:10.1089/jwh.2018.7084.
  20. Cho BS, Roh JW, Park J, et al. Safety and Efectiveness of Dienogest (Visanne®) for Treatment of Endometriosis: A Large Prospective Cohort Study. Reprod Sci. 2020. Mar;27(3):905-915. DOI:10.1007/ s43032-019-00094-5.
  21. Vercellini P, Bracco B, Mosconi P, et al. Norethindrone acetate or dienogest for the treatment of symptomatic endometriosis: A before and after study. Fertil Steril. 2016. Mar;105(3):734-743.e3. DOI:10. 1016/j.fertnstert.2015.11.016.
  22. Vercellini P, Pietropaolo G, De Giorgi O, et al. Treatment of symptomatic rectovaginal endometriosis with an estrogen-progestogen combination versus low dose norethindrone acetate. Fertil Steril. 2005. Nov;84(5):1375-87. DOI:10. 1016/j.fertnstert.2005.03.083.
  23. Ferrero S, Camerini G, Ragni N, et al. Norethisterone acetate in the treatment of colorectal endometriosis: A pilot study. Hum Reprod. 2010. Nov;84(5):1375-87. DOI:10.1093/humrep/dep361.
  24. Morotti M, Venturini PL, Biscaldi E, et al. Efcacy and acceptability of long-term norethindrone acetate for the treatment of rectovaginal endometriosis. Eur J Obstet Gynecol Reprod Biol. 2017. Jun:213:4-10. DOI:10.1016/j.ejogrb.2017.03.033.
  25. Crosignani PG, Luciano A, Ray A, Bergqvist A. Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain. Hum Reprod. 2006;21(1):248–56. DOI:10.1093/humrep/dei290.
  26. Vercellini P, Somigliana E, Vigano P, et al. Endometriosis: current therapies and new pharmacological developments. Drugs 2009;69:649–75. DOI: 10.2165/00003495-200969060-00002
  27. Somigliana E, Vigano P, Barbara G, Vercellini P. Treatment of endometriosis related pain: options and outcomes. Front Biosci (Elite Ed) 2009;1:455–65. DOI: 10.2741/e41.
  28. Committee Opinion No. 602. Depot medroxyprogesterone acetate and bone efects. Obstet Gynecol. 2014;123(6):1398–402. DOI:10.1097/01.AOG.0000450758.95422.c8.
  29. Razzi S, Luisi S, Ferretti C, et al. Use of a progestogen only preparation containing desogestrel in the treatment of recurrent pelvic pain after conservative surgery for endometriosis. Eur J Obstet Gynecol Reprod Biol. 2007;135(2):188–90. DOI:10.1016/j.ejogrb.2006.08.002.
  30. Olive DL, Pritts EA. Treatment of endometriosis. N Engl J Med 2001;345: 266–75. DOI: 10.1056/NEJM200107263450407.
  31. Maggiore ULR, Remorgida V, Scala C, et al. Desogestrel-only contraceptive pill versus sequential contraceptive vaginal ring in the treatment of rectovaginal endometriosis infltrating the rectum: a prospective open-label comparative study. Acta Obstet Gynecol Scand. 2014;93(3):239–47. DOI:10.1111/aogs.12326.
  32. Tekin YB, Dilbaz B, Altinbas SK, Dilbaz S. Postoperative medical treatment of chronic pelvic pain related to severe endometriosis: levonorgestrel-releasing intrauterine system versus gonadotropin-releasing hormone analogue. Fertil Steril. 2011;95(2):492–6. DOI:10.1016/j.fertnstert.2010.08. 042.
  33. Scholes D, LaCroix AZ, Ichikawa LE, et al. Change in bone mineral density among adolescent women using and discontinuing depot medroxyprogesterone acetate contraception. Arch Pediatr Adolesc Med 2005;159:139–44. DOI: 10.1001/archpedi.159.2.139.
  34. Lee KH, Jung YW, Song SY, et al. Comparison of the efcacy of diegnogest and levonorgestrel-releasing intrauterine system after laparoscopic surgery for endometriosis. J Obstet Gynaecol Res. 2018. Sep;44(9):1779-1786. DOI:10.1111/jog.13703.
  35. Chen Y-J, Hsu T-F, Huang B-S, et al. Postoperative maintenance levonorgestrel-releasing intrauterine system and endometrioma recurrence: a randomized controlled study. Am J Obstet Gynecol. 2017;216(6):582.e1-582.e9. DOI:10.1016/j.ajog.2017.02.008.
  36. Olive DL. Medical therapy of endometriosis. Semin Reprod Med. 2003;21(2):209–22. DOI:10.1055/s-2003-41327.
  37. Wattanayingcharoenchai R, Rattanasiri S, Charakorn C, et al. Postoperative hormonal treatment for prevention of endometrioma recurrence after ovarian cystectomy: a systematic review and network meta-analysis. BJOG An Int J Obstet Gynaecol. 2021. Jan;128(1):25-35. DOI:10.1111/1471-0528.16366.
  38. Chwalisz K, Perez MC, DeManno D, et al. Selective Progesterone Receptor Modulator Development and Use in the Treatment of Leiomyomata and Endometriosis. Endocr Rev. 2005;26(3):423–38. DOI:10.1210/ er.2005-0001.
  39. Goenka L, George M, Sen M. A peek into the drug development scenario of endometriosis – A systematic review. Biomed Pharmacother. 2017;90:575–85. DOI:10.1016/j.biopha. 2017.03.092.
  40. Islam MS, Afrin S, Jones SI, Segars J. Selective progesterone receptor modulators-mechanisms and therapeutic utility. Endocr Rev. 2020;41(5):bnaa012. DOI: 10.1210/endrev/bnaa01
  41. Bruner-Tran KL, Zhang Z, Eisenberg E, et al. Down-regulation of endometrial matrix metalloproteinase-3 and -7 expression in vitro and therapeutic regression of experimental endometriosis in vivo by a novel nonsteroidal progesterone receptor agonist, tanaproget. J Clin Endocrinol Metab. 2006;91(4):1554–60. DOI:10.1210/jc. 2005-2024.

Downloads

Published

2024-06-30

How to Cite

Markin, L., & Matvienko, O. (2024). Modern progestogens in the treatment of genital endometriosis: Literature review. REPRODUCTIVE ENDOCRINOLOGY, (72), 17–21. https://doi.org/10.18370/2309-4117.2024.72.17-21

Issue

No. 72 (2024)

Section

Gynecology

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

    1. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.